PORCINE EPIDEMIC DIARRHEA VIRUS (PEDV)
LEVELS: Highly unlikely: No controls necessary; Highly unlikely: No evidence of non-foodborne zoonotic transmission; Moderately effective: Requires high level of compliance with extraordinary on-farm biosecurity measures to prevent farm-to-farm transmission; Easy: Distinct clinical signs and/or existing test(s) available at local/regional laboratory(s); Substantial: Unsustainable acute or chronic losses related to severe clinical signs in a high prevalence of animals; Temporary disruption: Measureable negative effect on demand for less than a month when disease occurs on one or more farms; Minimal risk: Agent inherently unlikely to develop clinically important resistance to antibacterial or antiviral treatments; Minimal risk: Antibacterial or antiviral treatments rarely occur, or are typically limited to short-course individual animal therapy; No availability: Effective treatments not currently available in the US (or have not been developed); Available but uncertain efficacy: Commercial or autogenous vaccines exist in the US but protection may be inconsistent; Difficult and uncertain: Extremely difficult and with uncertain success rate, few global examples of success even at farm level
OVERVIEW
Porcine epidemic diarrhea virus (PEDV) is an alphacoronavirus causing acute enteric disease clinically similar to TGE but caused by a genetically and antigenically distinct virus. First recognized in Europe in the 1970s, PEDV gained global prominence when highly virulent strains emerged in China in 2010 and subsequently spread to the United States in April 2013, killing nearly seven million piglets during 2013-2014—representing an estimated 3-6% reduction in the US pig crop. Two main phylogenetic groups exist: classical (G1) strains circulating since the 1970s-1980s, and emerging (G2) strains that include highly virulent non-S INDEL variants and milder S INDEL variants distinguished by insertions and deletions in the spike gene. PEDV affects pigs of all ages with mortality approaching 100% in piglets under one week of age. By 2017, PEDV had spread to 39 US states and continues to cause sporadic outbreaks in previously affected and naive herds.
FOODBORNE ZOONOTIC TRANSMISSION POTENTIAL
Level: Highly unlikely: No controls necessary
PEDV is infectious only for swine and poses no known public health risk through food consumption. Despite extensive human exposure during the massive 2013-2014 US epidemic—when millions of piglets died and countless farm workers, veterinarians, and industry personnel had contact with infected animals and contaminated materials—no foodborne human infections have been documented. The virus maintains strict host specificity for pigs, and consumption or handling of pork products from recovered animals poses no food safety concern.
NON-FOODBORNE ZOONOTIC TRANSMISSION POTENTIAL
Level: Highly unlikely: No evidence of non-foodborne zoonotic transmission
No human infections with PEDV have been reported through any route despite decades of endemic circulation in Asia and massive epidemic exposure in North America and other regions. The virus does not replicate in human cells under natural conditions, and extensive occupational exposure during outbreaks—including direct contact with infected pigs, contaminated feces, and diagnostic sampling—has not resulted in documented human illness. Occupational exposure presents no infection risk to workers.
EFFECTIVENESS OF ON-FARM BIOSECURITY IN PREVENTING FARM-TO-FARM TRANSMISSION
Level: Moderately effective: Requires high level of compliance with extraordinary on-farm biosecurity measures to prevent farm-to-farm transmission
PEDV transmission is primarily fecal-oral through direct or indirect contact, but several indirect pathways bypass standard farm biosecurity. Contaminated equipment, transport vehicles, and personnel clothing/footwear have been epidemiologically linked to outbreaks. Most significantly, contaminated feed and feed ingredients have been implicated as transmission vehicles, including imported spray-dried porcine plasma products. Evidence for aerosol transmission exists in some experimental studies showing viable virus in air samples up to 16 km from infected farms during outbreaks, but other studies have not replicated these findings, and the epidemiological significance of airborne spread remains debated. PEDV RNA has been detected in 9.75% of wild boar in South Korea, and antibodies found in 3-4% of wild boar in Italy and Poland, though the role of feral swine in maintenance and ongoing transmission is unclear. The virus does not demonstrate the consistent long-distance airborne capacity of PRCV, but feed-based, fomite, and transport-related transmission creates spread pathways that bypass direct animal contact and challenge conventional biosecurity.
DIFFICULTY OF DETECTING AND CONFIRMING INFECTION
Level: Easy: Distinct clinical signs and/or existing test(s) available at local/regional laboratory(s)
PEDV diagnosis is well-supported by multiple validated methods readily available through veterinary diagnostic laboratories. Real-time RT-PCR is the standard diagnostic approach, with numerous validated singleplex and multiplex assays that differentiate PEDV from TGEV, PDCoV, rotavirus, and other enteric pathogens. Sequencing of amplified products can distinguish classical G1 strains from emerging G2 variants, and further differentiate non-S INDEL from S INDEL strains to characterize outbreak virulence. Virus isolation in Vero cells with trypsin supplementation is routine for research and vaccine production. Immunofluorescence, immunohistochemistry, and electron microscopy detect virus in tissues and feces. Multiple ELISA formats detect antibodies against N and S proteins for seroprevalence studies and herd immunity monitoring. The clinical presentation—acute onset of watery diarrhea, vomiting, and high neonatal mortality spreading rapidly through breeding herds—combined with widely available multiplex diagnostics makes detection and confirmation straightforward.
FINANCIAL IMPACT ON FARM'S COST OF PRODUCTION
Level: Substantial: Unsustainable acute or chronic losses related to severe clinical signs in a high prevalence of animals
PEDV causes severe economic losses during epidemic introductions into naive populations. The 2013-2014 US epidemic killed nearly seven million piglets and reduced the national pig crop by approximately 3-6%, representing billions of dollars in direct production losses at the farm level. Mortality approaches 100% in piglets under one week of age during acute outbreaks. Earlier Chinese outbreaks in 2010 killed over one million piglets in a single year across affected regions. Even after the epidemic phase resolves and endemic circulation establishes, PEDV persists through cycles of infection in weaning-age pigs losing maternal immunity, causing ongoing production inefficiency. Large breeding operations with multiple geographically separated farrowing units may experience prolonged outbreak duration as the virus spreads sequentially through facilities. Non-S INDEL strains cause significantly more severe disease than S INDEL variants, and strain identification has prognostic value for expected losses.
EFFECT ON DOMESTIC OR EXPORT MARKETS
Level: Temporary disruption: Measureable negative effect on demand for less than a month when disease occurs on one or more farms
PEDV is not an OIE-listed disease and does not trigger international trade restrictions between most trading partners, particularly since the virus has now spread to North America, South America, Asia, and Europe. However, the 2013-2014 US epidemic created significant temporary market disruption through supply reduction: massive piglet losses decreased market hog supplies several months later, temporarily elevating wholesale and retail pork prices. Consumer confidence was not affected (PEDV poses no food safety concerns), but production shortfalls created supply-driven price volatility. Some PEDV-free countries such as Australia maintain restrictions on imports from endemic countries, limiting market access. The primary market effect is supply-driven domestic price volatility during major outbreak periods rather than persistent trade barriers affecting export revenue.
PATHOGEN'S ABILITY TO DEVELOP AND SPREAD RESISTANCE
Level: Minimal risk: Agent inherently unlikely to develop clinically important resistance to antibacterial or antiviral treatments
PEDV is a viral pathogen that does not carry, acquire, or disseminate antimicrobial resistance genes. The virus contributes nothing to the AMR gene pool regardless of management approaches. Any antimicrobial use associated with PEDV outbreaks addresses secondary bacterial complications rather than the primary pathogen.
AMR DEVELOPMENT DRIVEN BY DISEASE MANAGEMENT
Level: Minimal risk: Antibacterial or antiviral treatments rarely occur, or are typically limited to short-course individual animal therapy
No antiviral treatments exist for PEDV, so disease management does not involve antimicrobials targeting the causative agent. Management strategies focus on supportive care for affected animals and development of lactogenic immunity through controlled exposure (feedback) or vaccination of breeding females. Antimicrobials are not routinely indicated for uncomplicated PEDV infection and would only be used for secondary bacterial complications. The rapid immune-mediated resolution of acute disease and emphasis on maternal immunity transfer rather than therapeutic intervention means PEDV infections generate minimal antimicrobial selection pressure across the affected population.
AVAILABILITY OF EFFECTIVE TREATMENT OPTIONS
Level: No availability: Effective treatments not currently available in the US (or have not been developed)
No specific antiviral treatments exist for PEDV infection. Management is entirely supportive: maintaining fluid and electrolyte balance to address dehydration from severe diarrhea, ensuring thermal comfort for piglets with limited thermoregulatory capacity, and facilitating piglet access to immune sows providing passive protection through antibody-rich milk. Treatment cannot alter the course of infection in already-affected animals—interventions simply support survival while the immune response develops and clears the virus. Research into host-virus interactions including spike protein-receptor binding and interferon antagonism may eventually identify therapeutic targets, but no practical treatments are currently available or anticipated in the near term for field application.
AVAILABILITY OF EFFECTIVE VACCINES OR BACTERINS
Level: Available but uncertain efficacy: Commercial or autogenous vaccines exist in the US but protection may be inconsistent
Multiple PEDV vaccines have been developed and marketed globally, but their field effectiveness has significant limitations. In China, vaccines based on classical CV777-like strains failed to protect against emerging highly virulent non-S INDEL strains, prompting development of new G2-based vaccines in 2016-2017 with improved but still imperfect efficacy. Korean vaccines derived from classical strains did not consistently induce protective lactogenic immunity against field challenge. Two US conditionally licensed vaccines—an alphavirus-vectored S protein vaccine and an inactivated whole virus product—induced relatively low virus-neutralizing antibody titers in colostrum and milk of vaccinated naive sows and provided limited protection to nursing piglets during challenge studies. The most effective protection against PEDV consistently comes from natural infection during mid-gestation, which stimulates robust mucosal immunity and high secretory IgA levels in colostrum and milk. Current industry practice typically combines controlled feedback exposure using virulent virus from outbreak materials with subsequent inactivated vaccine boosting to maintain immunity. Commercial vaccines help sustain herd immunity in previously exposed seropositive farms but perform poorly at initiating protective immunity in fully naive breeding populations.
FEASIBILITY OF ERADICATING THE DISEASE FROM THE US
Level: Difficult and uncertain: Extremely difficult and with uncertain success rate, few global examples of success even at farm level
PEDV can be eliminated from individual farms through coordinated management: controlled exposure to establish uniform sow immunity, strict implementation of McRebel-type protocols to break transmission chains, intensive farrowing management to prevent susceptible piglet exposure before maternal immunity transfer, and rigorous biosecurity including feed and transport sanitation. Multiple successful farm-level eliminations have been documented following the 2013-2014 US epidemic. However, regional or national elimination has not been achieved in any country following PEDV introduction. The virus persists through endemic cycles—continually infecting susceptible weaning-age pigs as maternal immunity wanes—and through periodic reintroductions via contaminated feed, transport vehicles, or other fomite pathways. Wild boar may serve as a minor reservoir in some regions, complicating area-wide approaches. Complete US eradication would require sustained industry-wide coordination including comprehensive feed biosecurity, standardized transport sanitation, addressing any wildlife reservoir role, and maintaining elimination status against reintroduction pressure—achievable in principle with existing knowledge and tools, but requiring substantial coordinated resources and commitment.